Skip to content
OpenCapital
Get started

Kyverna Therapeutics, Inc. KYTX Q1 2026 earnings

Reported May 12, 2026 · Before market open

Diluted EPS-$0.66Beat by $0.09
EPS estimate-$0.75

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.67

Financials

Q1 2026

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$596.4M+526%
Enterprise value$573.37M+1,393%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Versus estimates

Diluted EPS

Q1 2026-$0.66Beat by $0.09
Q4 2025-$0.80Beat by $0.04Q3 2025-$0.85Beat by $0.12Q2 2025-$0.97Beat by $0.03Q1 2025-$1.03Beat by $0.18Q4 2024-$0.88Miss by $0.01

Ask the moment Kyverna Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kyverna Therapeutics, Inc. report Q1 2026 earnings?
Kyverna Therapeutics, Inc. (KYTX) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Kyverna Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Kyverna Therapeutics, Inc. reported diluted EPS of $-0.66 for Q1 2026.
Did Kyverna Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.75 by $0.09.
How did Kyverna Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 35.9% from $-1.03.
Where can I find Kyverna Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219377) and the 10-Q periodic report (0001193125-26-219397) directly on SEC EDGAR. The filing index links above go to sec.gov.